🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10 results for “bimekizumab” Clear

  1. Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized), ustekinumab, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (authorized - MA number: 6697366.00.00), bimekizumab

    Pharma Mar S.A.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  2. bimekizumab

    Pharma Mar S.A.

    Axial Spondyloarthritis

    phase 3 small molecule active

    1 trial

  3. bimekizumab

    Pharma Mar S.A.

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  4. bimekizumab

    Pharma Mar S.A.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  5. bimekizumab

    Pharma Mar S.A.

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  6. bimekizumab

    Pharma Mar S.A.

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  7. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Pharma Mar S.A.

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  8. bimekizumab

    Pharma Mar S.A.

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  9. A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults

    Pharma Mar S.A.

    CCI

    phase 1 other active

    1 trial

  10. bimekizumab

    Pharma Mar S.A.

    Moderate to Severe Plaque Psoriasis, Psoriatic arthritis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources